The 10-second takeaway
For the quarter ended March 31 (Q1), CVS Caremark beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue was unchanged. Non-GAAP earnings per share grew significantly. GAAP earnings per share expanded significantly.
Margins grew across the board.
CVS Caremark reported revenue of $30.76 billion. The 20 analysts polled by S&P Capital IQ expected to see revenue of $30.35 billion on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.83. The 21 earnings estimates compiled by S&P Capital IQ predicted $0.79 per share. Non-GAAP EPS of $0.83 for Q1 were 28% higher than the prior-year quarter's $0.65 per share. GAAP EPS of $0.77 for Q1 were 31% higher than the prior-year quarter's $0.59 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 18.1%, 150 basis points better than the prior-year quarter. Operating margin was 5.5%, 90 basis points better than the prior-year quarter. Net margin was 3.1%, 60 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $31.26 billion. On the bottom line, the average EPS estimate is $0.93.
Next year's average estimate for revenue is $125.29 billion. The average EPS estimate is $3.96.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,701 members out of 1,766 rating the stock outperform, and 65 members rating it underperform. Among 455 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 444 give CVS Caremark a green thumbs-up, and 11 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on CVS Caremark is outperform, with an average price target of $58.17.
Is CVS Caremark the right retailer for your portfolio? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average retailing powerhouse. Click here for instant access to this free report.
- Add CVS Caremark to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.